Compare DMRC & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DMRC | NYXH |
|---|---|---|
| Founded | 2008 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 158.2M | 188.1M |
| IPO Year | N/A | 2021 |
| Metric | DMRC | NYXH |
|---|---|---|
| Price | $9.11 | $4.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $20.00 | $12.67 |
| AVG Volume (30 Days) | ★ 135.8K | 52.4K |
| Earning Date | 10-30-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $33,663,000.00 | $6,616,215.00 |
| Revenue This Year | N/A | $79.25 |
| Revenue Next Year | $7.63 | $297.08 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 10.96 |
| 52 Week Low | $6.35 | $4.35 |
| 52 Week High | $48.32 | $11.87 |
| Indicator | DMRC | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 57.72 | 47.87 |
| Support Level | $7.57 | $4.75 |
| Resistance Level | $9.64 | $5.00 |
| Average True Range (ATR) | 0.54 | 0.23 |
| MACD | 0.24 | 0.05 |
| Stochastic Oscillator | 83.89 | 71.43 |
Digimarc Corp is engaged in digital watermarking technologies. The Digimarc Illuminate platform is a distinctive software as a service (SaaS) cloud-based platform for digital connectivity that provides the tools for the application of digital watermarks and dynamic Quick Response (QR) codes, software (digital twins) that enables various systems and devices to interact with those data carriers and a centralized platform for capturing insights about digital interactions and automating activities based on that information. The company generates revenue through commercial and government applications of its technology. The company derives its revenue from software development services, subscriptions for products and related services, and licensing of patents.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.